沙利度胺、甲地孕酮联合营养支持方案对胃癌营养不良的疗效分析

Efficacy of Thalidomide and Megestrol Combined with Nutritional Support Program in Gastric Cancer with Malnutrition

目的:探讨沙利度胺、甲地孕酮联合营养支持方案在胃癌营养不良患者中的应用效果。方法:2021年2月-2022年1月石家庄市人民医院胃癌Ⅳ期患者提供的主观整体营养状况评量表评价C级患者,随机分为研究组(给予营养支持+甲地孕酮+沙利度胺治疗)、对照组(给予营养支持方案),各30例,统计分析两组患者的体重、体力状况、实验室指标、免疫功能、食欲变化、生存质量及不良反应发生情况。结果:研究组的体重、体力状况、营养学指标、炎性指标、免疫功能、厌食变化及生存质量均优于对照组,差异有统计学意义(P<0.05),不良反应可耐受。结论:沙利度胺、甲地孕酮联合营养支持方案在胃癌营养不良患者中的应用优于单纯应用营养支持治疗。

Objective:To investigate the application effect of thalidomide and megestrol combined with nutritional support program in malnutrition patients with gastric cancer. Methods: From February 2021 to January 2022, patients with gastric cancerat stage IV who were evaluated as Grade C according to patient-generated subjective global assessment in Shijiazhuang People’sHospital were randomly divided into the experimental group(nutritional support + megestrol + thalidomide treatment) and thecontrol group(nutritional support program), with 30 cases in each group. The body weight, physical condition, laboratory index,immune function, changes in appetite, quality of life, and adverse reactions in the two groups of patients were statisticallyanalyzed. Results: The body weight, physical condition, nutritional index, inflammatory index, immune function, change inanorexia and quality of life in the experimental group were better than those in the control group, with statistically significantdifferences(P<0.05). The adverse reactions were tolerable. Conclusion: The application of thalidomide and megestrol combinedwith nutritional support program in malnutrition patients with gastric cancer is better than that of nutritional support alone.